Onxeo S.A. buy Reibach111
Start price
13.06.17
/
50%
€5.39
Target price
26.06.17
€8.89
Performance (%)
-18.37%
End price
26.06.17
€4.40
Summary
This prediction ended on 26.06.17 with a price of €4.40. The prediction for Onxeo S.A. disappointed with a performance of -18.37%. Reibach111 has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | -4.064% | -4.064% | -73.593% | -86.752% |
| iShares Core DAX® | -1.215% | 4.788% | 16.604% | 15.523% |
| iShares Nasdaq 100 | -1.911% | 1.109% | 19.364% | 31.093% |
| iShares Nikkei 225® | -3.171% | 5.626% | 10.519% | 1.800% |
| iShares S&P 500 | -1.029% | 1.792% | 20.514% | 35.443% |
Comments by Reibach111 for this prediction
In the thread Onxeo S.A. diskutieren
Reibach111 stimmt der Buy-Einschätzung von Mori8 zu
Reibach111 stimmt am 13.06.2017 der Buy-Einschätzung von Mori8 mit dem Kursziel 8,888€ zu.Überschrift: ONXEO SA / Biotechnologie Frankreich
(Vom Mitglied beendet)